Omega Launches Aerium With ‘Substantial’ Cash, Two Antibodies Against SARS-CoV-2
Former Takeda Vaccines President Is CEO
Its antibodies will enter the clinic soon, but pandemic- and epidemic-focused Aerium plans to raise series B funds to take the assets all the way to an EUA in the US and pursue antiviral drug development.
You may also be interested in...
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
US FDA must rethink guidance on maintaining placebo-control in COVID-19 trials after any vaccine gets an EUA, companies say, arguing current proposal may not be ethical or feasible. Disease organizations who agree with the hurdles to preserving placebo-control maintain this is a reason why any EUA must meet a very high standard.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.